Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04720118 Recruiting - Covid19 Clinical Trials

Parkinson's Disease and Experiences Throughout the COVID-19 Pandemic

Start date: March 1, 2021
Phase:
Study type: Observational [Patient Registry]

The purpose of this research study is to examine the relationship between personal characteristics and satisfaction with care in those diagnosed with Parkinson's disease during the COVID-19 pandemic. Participants will take 4 different surveys regarding their satisfaction with care throughout the duration of the COVID-19 pandemic. The surveys in total should not take more than 30 minutes to complete

NCT ID: NCT04718285 Recruiting - COVID-19 Clinical Trials

Investigation the Effect of Montelukast in COVID-19

Start date: May 15, 2021
Phase: Phase 2
Study type: Interventional

Small molecule inhibitors have previously been investigated in different studies as possible therapeutics in the treatment of SARS-CoV-2. In the current drug repurposing study, the investigators identified the leukotriene (D4) receptor antagonist Montelukast as a novel agent that simultaneously targets two important drug targets of SARS-CoV-2. The investigators initially demonstrated the dual inhibition (main protease and Spike/ACE2) profile of Montelukast through multiscale molecular modeling studies. Next, the investigators characterized its effect on both targets by different in vitro experiments including the Fluorescent Resonance Energy Transfer (FRET)-based main protease enzyme inhibition assay, surface plasmon resonance (SPR) spectroscopy, pseudovirus neutralization on HEK293T / hACE2, and virus neutralization assay using xCELLigence MP real time cell analyzer.

NCT ID: NCT04717024 Recruiting - Covid19 Clinical Trials

The Nanowear Wearable Covid-19 Observational and Analysis Trend

NanoCOAT
Start date: September 15, 2020
Phase:
Study type: Observational

The NanoCOAT study is a multi-center, prospective, non-randomized, feasibility, observational, non-significant risk study. The NanoCOAT study will enroll a minimum of 10 and a maximum of 100 subjects in a potential for a multi-site in order to collect data and analyze physiological and biometric trends due to Covid-19.

NCT ID: NCT04716569 Recruiting - Covid19 Clinical Trials

Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19

Start date: January 20, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Ivermectin showed a strong viricidal effect upon covid19 virus in vitro as proved by many authors according to many studies , covid virus stay in postnasal space for 4 days before starting general manifestation, so ivermectin mucoadhesive nanosuspension sprayed inside the nose and post nasal space may help in early management of covid19 and may play a great rule in prophylaxis as well

NCT ID: NCT04716465 Recruiting - Covid19 Clinical Trials

Dysautonomia in Patients Post COVID-19 Infection

DYSCO
Start date: January 19, 2021
Phase:
Study type: Observational

The aim for this study is further to elucidate the presence of dysautonomia in post-covid-19 patients, by evaluating heart rate variability.

NCT ID: NCT04716179 Recruiting - Covid19 Clinical Trials

Prospective Two-arm Study of Fertility in Men With COVID-19

Start date: January 18, 2021
Phase: N/A
Study type: Interventional

COVID-19 infection is hypothesized to have a potentially negative effect on male fertility through direct damage to the testes. The current trial is aimed at investigating the effect of SARS-CoV-2 on fertility and determining if viral bodies are capable of directly damaging testicular cells

NCT ID: NCT04716023 Recruiting - Asthma Clinical Trials

Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19

PASSPORT
Start date: August 23, 2019
Phase:
Study type: Observational

The purpose of this research project is to study small airways physiological function in patients with chronic obstructive lung disease or COVID-19 and explore the relationship with in-vivo microanatomical small airway structure as measured by OCT. Correlating endobronchial assessment with multiple breath nitrogen washout and impulse oscillometry will allow the characterisation of the relationship between small airway structural findings and these validated investigations. A small volume lung wash, endobronchial brushings and the collection of a limited number of endobronchial cryobiopsy samples will be performed to better understand the endobronchial environment of the small airways through inflammatory studies. Following the completion of any such work, residual samples will be stored in a "bio-bank" to enable the completion of future work. Understanding the relationship with symptom-based quality of life scoring questionnaires and a functional assessment of exercise capacity will help elucidate the clinical impact of in-vivo small airways findings.

NCT ID: NCT04715360 Recruiting - Covid19 Clinical Trials

Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy

Start date: December 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing rapidly since the first case found in March 2020 to date. Coronavirus 2 (SARS-CoV-2) virus disrupts human normal immune system resulting in uncontrolled inflammatory response. Based on our research and experience in doing cell therapy for 9 years, activated platelet-rich plasma (PRP) produces anti-inflammatory effects in inflammatory condition that is beneficial for tissue regeneration. In this study, we aimed to evaluate the potential of autologous activated platelet-rich plasma (aaPRP) and the outcomes for treating severe Coronavirus Disease-2019 (COVID-19) patients in Intensive Care Unit (ICU).

NCT ID: NCT04715295 Recruiting - COVID-19 Clinical Trials

Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19

DOXYCOV
Start date: October 5, 2020
Phase: Phase 4
Study type: Interventional

This is an exploratory study to evaluate the efficacy of Doxycycline (200mg on D1 to D7) and Rivaroxaban (15 mg daily on D1 to D7) versus the combination of Hydroxychloroquine (400 mg on D1 to D7) and Azithromycin (500 mg on D1 and 250mg on D2 to D5) as per national standard to treat ambulatory mild COVID-19 patients, with the aim to achieve early negativity of RT-PCR of SARS-CoV-2 from nasopharyngeal swab, and early clinical improvement and prevention of severe disease.

NCT ID: NCT04714125 Recruiting - Covid19 Clinical Trials

Prognostic Value of Flow-mediated Dilation in Hospitalized COVID-19 Patients

Start date: June 19, 2020
Phase:
Study type: Observational

This study will evaluate the associations between vascular parameters and clinical outcomes in patients hospitalized with COVID-19. The vascular function and structure of individuals with COVID-19 admitted to the General Hospital of the University of Sao Paulo will be assessed in the first 72 hours of hospitalization. Then, participants will be followed up until hospital discharge/death. Logistical regressions will be run to evaluate if vascular function/structure can predict ICU admissions, intubation, thrombosis or death.